#1 Clinical Trials Search in Europe

Ly3819469 Sodium

LY3819469 Sodium, also known as Lepodisiran, is an investigational drug currently being studied in clinical trials for its potential to treat lipoprotein disorders, particularly in patients with elevated levels of Lipoprotein(a) [Lp(a)]. This article provides an overview of the ongoing research, including the drug’s mechanism of action, target population, and potential benefits in reducing cardiovascular risks associated with high Lp(a) levels.

Table of Contents

What is LY3819469 SODIUM?

LY3819469 SODIUM, also known as Lepodisiran, is a new investigational drug being studied for its potential to treat high levels of Lipoprotein(a), or Lp(a) for short[1][2]. It belongs to a class of drugs called synthetic siRNA (small interfering RNA), which are designed to target specific genetic material in the body[1].

Medical Conditions Treated

LY3819469 SODIUM is being studied to treat the following conditions:

  • Lipoprotein Disorder: Specifically, elevated levels of Lipoprotein(a)[1]
  • Atherosclerotic Cardiovascular Disease (ASCVD): A condition where plaque builds up in the arteries, potentially leading to serious cardiovascular events[2]

Lipoprotein(a) is a type of cholesterol that, when present in high levels, can increase the risk of heart disease, stroke, and other cardiovascular problems.

How LY3819469 SODIUM Works

LY3819469 SODIUM is designed to reduce the levels of Lipoprotein(a) in the blood. As a synthetic siRNA, it works at the genetic level by interfering with the production of Lp(a) in the liver[1]. This approach is different from traditional cholesterol-lowering medications and may offer a new option for patients with high Lp(a) levels that don’t respond well to other treatments.

Clinical Trials

LY3819469 SODIUM is currently being studied in two major clinical trials:

  1. Phase 2 Trial (EZEB): This study aims to investigate the efficacy and safety of LY3819469 in adults with elevated Lipoprotein(a) levels. The main goal is to evaluate if LY3819469 is superior to placebo in reducing Lp(a) levels[1].
  2. Phase 3 Trial (ACCLAIM-Lp(a)): This larger study is investigating whether Lepodisiran (LY3819469) can reduce the risk of major adverse cardiovascular events in adults with high Lp(a) levels who either have established atherosclerotic cardiovascular disease or are at risk for a first cardiovascular event[2].

Who Can Receive LY3819469 SODIUM?

Based on the clinical trial criteria, potential candidates for LY3819469 SODIUM treatment include:

  • Adults aged 40 years or older (for the Phase 2 trial)[1]
  • Adults aged 18 years or older with established ASCVD, or 55 years or older at risk for a first cardiovascular event (for the Phase 3 trial)[2]
  • Individuals with Lp(a) levels ≥175 nmol/L[1][2]
  • People with a body mass index between 18.5 and 40 kg/m² (for the Phase 2 trial)[1]

However, certain conditions may exclude participation, such as:

  • Recent major cardiovascular events or surgeries[1][2]
  • Uncontrolled diabetes or high blood pressure[1]
  • Severe heart failure or kidney disease[2]
  • Certain liver conditions[2]

How is LY3819469 SODIUM Administered?

LY3819469 SODIUM is administered as a subcutaneous injection, which means it’s injected just under the skin[1]. The exact dosing schedule is still being studied in the clinical trials.

Potential Benefits

The potential benefits of LY3819469 SODIUM treatment include:

  • Significant reduction in Lipoprotein(a) levels[1]
  • Possible reduction in the risk of major adverse cardiovascular events, such as heart attack, stroke, and the need for urgent coronary procedures[2]
  • A new treatment option for patients who haven’t responded well to other lipid-lowering therapies

Important Considerations

While LY3819469 SODIUM shows promise, it’s important to remember:

  • It’s still an investigational drug and not yet approved for general use
  • The full range of potential side effects is still being studied
  • Long-term effects and benefits are not yet known
  • It may not be suitable for everyone with high Lp(a) levels

As research continues, more information about LY3819469 SODIUM’s effectiveness and safety will become available. If you have high Lp(a) levels or are at risk for cardiovascular disease, discuss with your doctor whether participating in a clinical trial or considering this treatment in the future might be appropriate for you.

Aspect Details
Drug Name LY3819469 Sodium (Lepodisiran)
Drug Type Synthetic siRNA (small interfering RNA)
Administration Solution for injection, subcutaneous
Target Condition Elevated Lipoprotein(a) [Lp(a)] levels (≥175 nmol/L)
Primary Objectives Reduce Lp(a) levels, decrease risk of major adverse cardiovascular events
Study Phases Phase 2 and Phase 3 clinical trials
Key Inclusion Criteria Adults ≥40 years (Phase 2), Adults ≥18 years with ASCVD or ≥55 years at risk (Phase 3)
Primary Endpoints Percent change in Lp(a) levels, time to first MACE-4 event
Potential Benefits Reduction in cardiovascular risk for patients with high Lp(a) levels

FAQ

  • What is LY3819469 Sodium, and how does it work? LY3819469 Sodium, also known as Lepodisiran, is a synthetic siRNA (small interfering RNA) drug designed to reduce Lipoprotein(a) [Lp(a)] levels in the body. It works by targeting specific genetic material involved in the production of Lp(a), potentially lowering its levels in the bloodstream.
  • Who might benefit from LY3819469 Sodium treatment? The drug is being studied in adults with elevated Lp(a) levels, typically 175 nmol/L or higher. It may benefit individuals with established atherosclerotic cardiovascular disease or those at risk for a first cardiovascular event, especially if they have high Lp(a) levels.
  • What are the main objectives of the clinical trials for LY3819469 Sodium? The primary objectives are to evaluate if LY3819469 Sodium is superior to placebo in reducing Lp(a) levels and to investigate its potential in reducing the risk of major adverse cardiovascular events (MACE) in adults with elevated Lp(a).
  • How is LY3819469 Sodium administered? LY3819469 Sodium is administered as a solution for injection, typically given subcutaneously (under the skin). The exact dosing schedule and amount are being investigated in the clinical trials.
  • What are the potential benefits of LY3819469 Sodium? If successful, LY3819469 Sodium could offer a new treatment option for reducing Lp(a) levels, which may lead to a decreased risk of cardiovascular events such as heart attacks, strokes, and the need for urgent coronary revascularization in high-risk individuals.

Ongoing Clinical Trials on Ly3819469 Sodium

  • Study of LY3819469 for Adults with High Lipoprotein(a) Levels

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany The Netherlands Romania Spain

Glossary

  • Lipoprotein(a) [Lp(a)]: A type of lipoprotein (fat-protein particle) in the blood that is associated with an increased risk of cardiovascular disease when present at high levels.
  • Atherosclerotic Cardiovascular Disease (ASCVD): A condition where plaque builds up inside the arteries, potentially leading to heart attacks, strokes, or other cardiovascular problems.
  • siRNA (small interfering RNA): A type of molecule that can interfere with the expression of specific genes, potentially reducing the production of certain proteins in the body.
  • Major Adverse Cardiovascular Events (MACE): A combined measure of serious heart-related outcomes, typically including events like heart attacks, strokes, and cardiovascular death.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against a non-treatment option.
  • Subcutaneous injection: A method of administering medication by injecting it into the layer of tissue just beneath the skin.
  • Revascularization: A medical procedure to restore blood flow to a part of the body, often used in treating blocked arteries in the heart.
  • Lipid-lowering drugs: Medications used to reduce levels of fats (lipids) in the blood, such as cholesterol and triglycerides.
  • Body Mass Index (BMI): A measure that uses your height and weight to work out if your weight is healthy, calculated by dividing weight in kilograms by height in meters squared.
  • Nanomoles per liter (nmol/L): A unit of measurement used to express the concentration of substances in blood or other bodily fluids.

References

  1. http://clinicaltrials.eu/trial/study-of-ly3819469-for-adults-with-high-lipoproteina-levels/
  2. http://clinicaltrials.eu/trial/study-on-lepodisiran-for-reducing-cardiovascular-events-in-adults-with-high-lipoproteina-and-atherosclerotic-cardiovascular-disease/